Stock report · Delisted · Nasdaq
Sonnet Biotherapeutics Holdings Inc (SONN)
1.26USD Delisted Final close · Dec 2, 2025
SONN no longer trades. Sonnet Biotherapeutics Holdings was delisted from the Nasdaq in December 2025.
All prices on this page are historical. The last trade was on December 2, 2025, at $1.26.
SONN stock price history
Final trading statistics
- Final close
- $1.26
- Final trading day
- Dec 2, 2025
- Market cap at delisting
- $8.60M
- Shares outstanding
- 6.83M
- Final 52-week range
- $1.08 – $19.30
- Avg. volume (final 3 mo.)
- 1,078,698
- All-time high
- $1000000.00 · Jul 2005
- All-time low
- $1.11 · Jun 2025
- Return since IPO
- -100.0%
- Beta
- 1.47
- Book value / share
- −$0.91
- Price / book
- -1.38
About Sonnet Biotherapeutics Holdings Inc
Sonnet BioTherapeutics Holdings, Inc. was a biotechnology company with a platform for biologic drugs that act on one or two targets. Its fully human albumin binding technology used single chain antibody fragments that attach to human serum albumin to reach target tissues.
Its lead candidate, SON-1010, was a single-chain form of interleukin 12 aimed at solid tumors such as ovarian, non-small cell lung and head and neck cancers. SON-080, a form of interleukin 6, targeted chemotherapy-induced and diabetic peripheral neuropathy. Other programs included SON-1210 for solid tumors such as colorectal cancer, SON-1411 combining an IL-18 binding protein with IL-12, and SON-1400, a fusion protein linked to the FHAB.
The company licensed an interleukin-6 preparation to New Life Therapeutics Pte, Ltd. and worked with Sarcoma Oncology Center on SON-1210. Based in Princeton, New Jersey, it was acquired by Hyperliquid Strategies Inc in a reverse merger as of December 2, 2025. The stock was delisted from the Nasdaq that month, with a final trade on December 2, 2025 at $1.26.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Princeton, NJ
- Employees
- 13
- IPO date
- October 31, 2006
- Delisted
- December 2, 2025
- SEC CIK
- 1106838
Sonnet Biotherapeutics financials before the delisting
The last 5 fiscal years Sonnet Biotherapeutics reported as a public company, fiscal year ending September.
SONN revenue and net income
SONN earnings per share
SONN annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $1.00M | −$16.1M | — |
| FY2024 | $18.6K | −$7.4M | −$11.33 |
| FY2023 | $147.8K | −$18.8M | −$3.36 |
| FY2022 | $349.9K | −$29.8M | −$6.85 |
| FY2021 | $483.6K | −$25.0M | −$3.43 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Sonnet Biotherapeutics stock FAQ
What happened to Sonnet Biotherapeutics stock?
Sonnet Biotherapeutics Holdings was delisted from the Nasdaq in December 2025. The final close was $1.26 on December 2, 2025.
Can I still buy SONN stock?
No. SONN is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on December 2, 2025.
What was the last price of SONN?
SONN last closed at $1.26 on December 2, 2025, which valued the company at about $8.60M.
How did Sonnet Biotherapeutics do in its last full fiscal year?
In fiscal 2025, its last full year as a public company, Sonnet Biotherapeutics reported revenue of $1.00M and net income of −$16.1M.
When did Sonnet Biotherapeutics go public?
Sonnet Biotherapeutics shares started trading on October 31, 2006.
SONN no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.